MedPath

HIIT Following Breast Cancer Chemotherapy

Not Applicable
Recruiting
Conditions
Breast Cancer
Interventions
Behavioral: 12-week Intervention Period
Behavioral: 12-week Observation Period
Registration Number
NCT05913713
Lead Sponsor
University of Florida
Brief Summary

Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
158
Inclusion Criteria
  • female patients based on biological sex
  • 18 to 85 years of age
  • diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer
  • completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation
  • absence of contraindications to exercise or to participate in study
  • study clinician approval
Exclusion Criteria
  • do not meet inclusion criteria
  • scheduled to receive surgery or radiation therapy during the intervention period
  • any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
  • lymphedema stage ≥2 prior to study enrollment
  • are pregnant
  • current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Moderate Intensity Continuous Training (MICT)12-week Observation PeriodSupervised home-based moderate-intensity continuous training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
High Intensity Interval Training (HIIT)12-week Observation PeriodSupervised home-based high-intensity interval training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
Usual Care (UC)12-week Observation PeriodResearch participants will continue their habitual physical activity for the duration of the study. Once they complete the study, they will have the opportunity to perform supervised HIIT or MICT at home for 3 days/week for 12 weeks (research participants can choose either type of exercise).
Usual Care (UC)12-week Intervention PeriodResearch participants will continue their habitual physical activity for the duration of the study. Once they complete the study, they will have the opportunity to perform supervised HIIT or MICT at home for 3 days/week for 12 weeks (research participants can choose either type of exercise).
High Intensity Interval Training (HIIT)12-week Intervention PeriodSupervised home-based high-intensity interval training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
Moderate Intensity Continuous Training (MICT)12-week Intervention PeriodSupervised home-based moderate-intensity continuous training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
Primary Outcome Measures
NameTimeMethod
Percent completed vs. planned exercise durationThroughout the 12 weeks of supervised home-based exercise training

The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise min/session.

Change in brachial FMDBaseline, Following a 12-week intervention period, Following a 12-week observation period

Flow-mediated dilation (FMD) is an established non-invasive measure of endothelial function. Brachial artery FMD will be determined via ultrasonography in response to reactive hyperemia following 5-min forearm ischemia.

Change in cardiac function (global longitudinal strain)Baseline, Following a 12-week intervention period, Following a 12-week observation period

Global longitudinal strain is a marker of acute subclinical cardiotoxicity and is recommended for monitoring cancer patients at risk of cancer therapy-related cardiac dysfunction.

Percent completed vs. planned exercise frequencyThroughout the 12 weeks of supervised home-based exercise training

The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise sessions/week.

Percent completed vs. planned exercise intensityThroughout the 12 weeks of supervised home-based exercise training

The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise intensity/session.

Number of participants who experience adverse events as defined by most recent CTCAE throughout the exercise interventionThroughout the 12 weeks of supervised home-based exercise training

To evaluate safety plans are in place for determination and monitoring of adverse events according to the most recent National Cancer Institute Common Terminology Criteria for Adverse Events. Classification for seriousness, expectedness, severity and relationship to study intervention will be based on the NIH provided definitions.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Integrative Cardiovascular Physiology Laboratory, University of Florida

🇺🇸

Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath